Compare Abeona Therapeutics Inc (ABEO) vs Verizon Communications Inc (VZ) Price & Performance

ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.

The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.

Verizon (VZ) trades at $47.03, down 0.06% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $49.69. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $1.30 surpassing the $1.27 estimate. The company maintains strong cash flow from operations at $37.14 billion in 2025 and a healthy dividend yield, supported by a $0.71 per share payout scheduled for August 2026.

VZ presents a value opportunity with a low P/E of 12.31 and stable revenue around $138 billion, though competitive pressures from new entrants like SpaceX's Starlink and high debt levels pose risks. Analyst sentiment is mixed with 36.7% buy ratings, but fundamentals suggest resilience for income-focused investors seeking telecom exposure.